- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06024603
Individualized Treatments in Adults With Relapsed/Refractory Cancers
April 22, 2024 updated by: Case Comprehensive Cancer Center
A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants.
This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Treatment itself will not be given as part of this trial.
The results of the drug sensitivity test (DST) and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices.
The physician will decide the most appropriate treatment for each case, with the option to add one or more personalized (assay-guided) drug(s) from the investigational platform.
All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Diana Azzam, PhD
- Phone Number: 305-348-9043
- Email: dazzam@fiu.edu
Study Contact Backup
- Name: Jorge Manrique-Succar, MD
- Phone Number: (954) 659-5000
- Email: manriqj@ccf.org
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33199
- Recruiting
- Florida International University
-
Contact:
- Diana Azzam, PhD
- Phone Number: 305-348-9043
- Email: dazzam@fiu.edu
-
Principal Investigator:
- Diana Azzam, PhD
-
Weston, Florida, United States, 33331
- Recruiting
- Lerner College of Medicine, Cleveland Clinic Florida
-
Principal Investigator:
- Jorge Manrique-Succar, MD
-
Sub-Investigator:
- Elizabeth Stone, MD
-
Sub-Investigator:
- Chebli Mrad, MD
-
Sub-Investigator:
- Badih Adada, MD
-
Sub-Investigator:
- Rafael Arleta-Bulos, MD
-
Sub-Investigator:
- Diana Saravia, MD
-
Sub-Investigator:
- Arun Nagarajan, MD
-
Sub-Investigator:
- Thomas Samuel, MD
-
Sub-Investigator:
- Chakra Chaulagain, MD
-
Sub-Investigator:
- Chieh-Lin Fu, MD
-
Sub-Investigator:
- Amer Hanano, MD
-
Sub-Investigator:
- Candice Schwartz, MD
-
Sub-Investigator:
- Mariana Berho, MD
-
Contact:
- Jillian King
- Phone Number: 954-299-5798
- Email: kingj19@ccf.org
-
Contact:
- Kaitlin Bernabe
- Phone Number: 56449 954-659-5000
- Email: BERNABK@ccf.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity.
- Patients with suspected or confirmed diagnosis of recurrent or refractory cancer.
- Participants who have undergone at least two lines of previous therapy.
- Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers).
- Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing.
- Participants willing to sign informed consent.
Exclusion Criteria:
- Participants who do not have malignant tissue available and accessible.
- Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling.
- Participants with newly diagnosed tumors and tumors that have high (>90%) cure rate with safe standard therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug Sensitivity Testing
The results of the DST and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices.
The physician will decide which treatment will be most appropriate for each case.
All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.
|
Refractory cancer tissue will be collected from participants and subjected to single-drug testing while DNA is simultaneously sent for targeted gene sequencing.
Drug sensitivity scores from the tests will become available for a final list of therapeutic options ranked best in order of preference together with suggested doses and schedules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment recommendation feasibility
Time Frame: Up to 4 weeks post-treatment
|
Primary objective is to determine feasibility of providing treatment recommendations to relapsed and refractory adult cancer patients based on ex vivo drug sensitivity testing (DST).
Feasibility will be demonstrated if it is possible to recommend treatment within 4 weeks in at least 22 of 36 participants (62.5%).
|
Up to 4 weeks post-treatment
|
Treatment recommendation feasibility
Time Frame: Up to 4 weeks post-treatment
|
Primary objective is to determine feasibility of providing treatment recommendations to relapsed and refractory adult cancer patients based on genomic profiling.
Feasibility will be demonstrated if it is possible to recommend treatment within 4 weeks in at least 22 of 36 participants (62.5%).
|
Up to 4 weeks post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment responsiveness
Time Frame: Up tp 1 year post-treatment
|
Treatment responsiveness will be measured by comparing individual outcomes of adult participants with relapsed and refractory cancers treated with DST-guided therapy to non-DST guided (conventional) therapy.
To address this goal, the overall response rate will be calculated.
A responder to the treatment will be defined as any patient who achieves a best response of "partial response" or "complete response" during the study period.
Evaluable patients who demonstrate a complete or partial response confirmed by physician's review will be considered a responder.
All other evaluable patients will be considered non- responder.
Outcomes will be observed during treatment and follow-up for one year post-treatment or until disease progression, death, or withdrawal, whichever occurs first.
|
Up tp 1 year post-treatment
|
Progression-free survival
Time Frame: Up tp 1 year post-treatment
|
Progression-free survival will be measured by comparing individual outcomes of participants with relapsed and refractory cancers treated with DST-guided therapy to non-DST guided (conventional) therapy.
DFS will be defined as time from start of treatment to even (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free.
Outcomes will be observed during treatment and follow-up for one year post-treatment or until disease progression, death, or withdrawal, whichever occurs first.
|
Up tp 1 year post-treatment
|
Progression-free survival ratio
Time Frame: Up to 1 year post-treatment
|
We will assess changes in progression-free survival from each patient's previous treatment versus their progression-free survival from the treatment assigned during the trial.
Assessments will be made both in the DST-guided cohort and the non-DST-guided (conventional) cohort.
Analysis will include both the raw ratio as well as the number of incidences of 30% improved PFS on trial versus previous regimen (PFS2/PFS1 > 1.3x).
|
Up to 1 year post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jorge Manrique-Succar, MD, Lerner College of Medicine, Cleveland Clinic Florida
- Principal Investigator: Diana Azzam, PhD, Robert Stempel College of Public Health and Social Work, Florida International University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2023
Primary Completion (Estimated)
November 1, 2025
Study Completion (Estimated)
November 1, 2025
Study Registration Dates
First Submitted
July 28, 2023
First Submitted That Met QC Criteria
September 1, 2023
First Posted (Actual)
September 6, 2023
Study Record Updates
Last Update Posted (Actual)
April 23, 2024
Last Update Submitted That Met QC Criteria
April 22, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- CASE5Y22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed Cancer
-
The Hospital for Sick ChildrenCompleted
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
HotSpot Therapeutics, IncRecruitingSolid Tumor, Adult | Relapsed Cancer | Refractory CancerUnited States
-
Gilead SciencesTerminatedHuman Papillomavirus (HPV) 16+ Relapsed/Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterHuman Animal Bond Research InstituteCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
CytoMed Therapeutics Pte LtdNational University Hospital, SingaporeNot yet recruitingCancer | Malignancy | Relapsed Cancer | Refractory CancerSingapore
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor, Adult | Refractory Cancer | Relapsed Solid Neoplasm
-
Merck Sharp & Dohme LLCCompletedRelapsed or Refractory Advanced Cancer
Clinical Trials on Drug Sensitivity Test (DST)
-
Affiliated Hospital of Jiangnan UniversityRecruitingLung Cancer | OrganoidChina
-
Zhejiang Cancer HospitalCompletedPathological Conditions, Signs and SymptomsChina
-
Peking University Cancer Hospital & InstituteUnknown
-
Ruijin HospitalChongqing Kingbiotech Co.,LtdNot yet recruitingAdvanced Pancreatic Neuroendocrine TumorChina
-
The Children's Hospital of Zhejiang University...College of Pharmaceutical Science at Zhejiang UniversityRecruitingAcute Myeloid Leukemia in ChildrenChina
-
Center of Implantology, Oral and Maxillofacial...CompletedPeri-Implantitis | Peri-implant Mucositis | Sensitivity | Peri-Implantational LossSpain
-
Johns Hopkins UniversityBoston Medical CenterCompleted
-
Peking Union Medical College HospitalRecruitingColo-rectal CancerChina
-
Hadassah Medical OrganizationUnknownCoronary Stent RestenosisIsrael
-
Changhai HospitalRecruiting